Local and spatial factors determining HIV-1 protease substrate recognition.
暂无分享,去创建一个
J. Kupiec | S Hazebrouck | P Sonigo | V Machtelinckx-Delmas | J J Kupiec | P. Sonigo | S. Hazebrouck | V. Machtelinckx-Delmas
[1] B. Moss,et al. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[2] E Harper,et al. On the size of the active site in proteases: pronase. , 1972, Biochemical and biophysical research communications.
[3] J. Louis,et al. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. , 1992, Biochemistry.
[4] A. Tomasselli,et al. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. , 1991, The Journal of biological chemistry.
[5] T. Kunkel. Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[6] A. Wlodawer,et al. [14]Subsite preferences of retroviral proteinases , 1994 .
[7] F. Mammano,et al. Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.
[8] F. de la Cruz,et al. pACYC184-derived cloning vectors containing the multiple cloning site and lacZ alpha reporter gene of pUC8/9 and pUC18/19 plasmids. , 1988, Gene.
[9] C. Hutchison,et al. Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli. , 1987, Science.
[10] C. Debouck,et al. Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease. , 1992, Biochemistry.
[11] A. Tomasselli,et al. Discovery and design of HIV protease inhibitors as drugs for treatment of aids , 1996 .
[12] D. Veber,et al. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. , 1988, Biochemical and biophysical research communications.
[13] J. Sodroski,et al. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[14] R M Stroud,et al. Atomic structure of thymidylate synthase: target for rational drug design. , 1987, Science.
[15] C. Hutchison,et al. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.
[16] L J Davis,et al. Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[17] HIV-1 Protease , 2000 .
[18] E. Wimmer,et al. Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase , 1990, Journal of virology.
[19] A. Wlodawer,et al. Subsite preferences of retroviral proteinases. , 1994, Methods in enzymology.
[20] D. Lamarre,et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.
[21] J. Hansen,et al. Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody. , 1988, The EMBO journal.
[22] J. Falloon,et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.
[23] T. Leste-Lasserre,et al. Conversion of Thymidylate Synthase into an HIV Protease Substrate* , 1996, The Journal of Biological Chemistry.
[24] M. Belfort,et al. Primary structure of the Escherichia coli thyA gene and its thymidylate synthase product. , 1983, Proceedings of the National Academy of Sciences of the United States of America.